Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NFS-02 Gene Therapy for LHON Associated with ND1 Mutation
NCT05820152Phase 2Terminated
- Sponsor
- Neurophth
- Start
- Aug 2023
- Primary completion
- Jun 2024
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
A Phase 2 trial of NFS-02 in Leber hereditary optic neuropathy (LHON), sponsored by Neurophth. Started Aug 2023; status: terminated.
02
Drugs
NFS-02
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT05820152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05820152.